嵌合抗原受体T淋巴细胞治疗神经母细胞瘤的研究进展

嵌合抗原受体T淋巴细胞(chimeric antigen receptor T lymphocyte,CAR-T)免疫治疗是近年来开始出现的一种新型肿瘤免疫治疗方法,目前已经在白血病、淋巴瘤等晚期癌症患者中应用,并取得一定疗效.神经母细胞瘤是儿童最常见的颅外恶性实体肿瘤之一,有超过一半的患者在确诊时已经发生了转移.目前高危患儿的预后较差,临床需要寻找新的治疗方法.该文总结了CAR-T的基本结构及优化发展,讨论了其在神经母细胞瘤中的治疗原理及风险,并展望了CAR-T在实体肿瘤中的治疗前景.

Chimeric antigen receptor T lymphocyte immunotherapy of neuroblastoma

Chimeric antigen receptor T lymphocyte immunological therapy (CAR-T)is a new oncologic immunotherapy in recent years,which has been widely used in patients with leukemia and lymphoma and achieved a certain effect.Neuroblastoma is one of the most common extracranial solid tumors in children and over 50％ of patients have metastatic recurrence when first diagnosed.The prognosis for the high-risk neuroblastoma remains poor at the moment and it's time to look for new treatments.In this review,we summarize the basic structure and development of CAR-T,discuss the principles and risks of CAR-T in the treatment of neuroblastoma,and give an outlook to CAR-T in the treatment of solid tumors.